WATERTOWN, Mass., April 08, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, ...
In November 2023, C4T made the strategic decision to discontinue clinical development of CFT8634 based on clinical data from the Phase 1 trial. About C4 Therapeutics C4 Therapeutics is a ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback